Financials in USD. Standardized financial statements.
A compact view of how Crescita Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $21.10M | $19.58M | $17.52M | $23.52M | $16.77M | $15.64M | $22.34M | $16.63M | $12.01M | $3.50M |
| Revenue Growth? | +7.8% | +11.7% | -25.5% | +40.3% | +7.2% | -30.0% | +34.3% | +38.4% | +242.9% | 0.0% |
| Cost of Revenue? | $10.74M | $9.97M | $7.16M | $10.34M | $6.75M | $4.37M | $5.80M | $5.54M | $4.85M | $2.33M |
| Gross Profit? | $10.36M | $9.61M | $10.36M | $13.18M | $10.01M | $11.27M | $16.54M | $11.09M | $7.17M | $1.17M |
| Gross Margin? | +49.1% | +49.1% | +59.1% | +56.0% | +59.7% | +72.1% | +74.0% | +66.7% | +59.7% | +33.4% |
| Operating Expenses? | $11.39M | $12.82M | $12.32M | $12.65M | $10.73M | $9.72M | $11.57M | $11.13M | $13.36M | $15.74M |
| Operating Income? | -$1.02M | -$3.21M | -$1.96M | $529,000 | -$719,000 | $1.55M | $4.97M | -$37,000 | -$6.57M | -$14.57M |
| EBITDA? | $478,609 | -$1.33M | -$450,000 | $2.00M | $606,000 | $2.26M | $6.70M | $1.11M | -$4.96M | -$14.03M |
| Income Before Tax | -$82,931 | -$2.76M | -$1.53M | $404,000 | -$1.01M | $520,000 | $3.18M | $649,000 | -$11.26M | -$14.80M |
| Income Tax Expense | $8,992 | -$14,000 | $456,000 | -$458,000 | $96,000 | $483,000 | $1.32M | -$1.77M | $651,000 | -$2.10M |
| Net Income? | -$91,924 | -$2.75M | -$1.99M | $862,000 | -$1.10M | $37,000 | $1.85M | $2.40M | -$11.46M | -$14.95M |
| EPS? | $-0.00 | $-0.14 | $-0.10 | $0.04 | $-0.05 | $0.00 | $0.09 | $0.12 | $-0.82 | $-1.17 |
| Diluted EPS? | $-0.00 | $-0.14 | $-0.10 | $0.04 | $-0.05 | $0.00 | $0.08 | $0.12 | $-0.82 | $-1.17 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality